Cancer update

prism-facetsBreast Cancer Patients with Highest HER2 Levels Benefit Most from Kadcyla

Women with metastatic breast cancer and high tumor expression of HER2 taking Kadcyla had a greater overall survival benefit than women with lower HER expression, according to new data from the EMELIA trial, which was released at the annual meeting of the American Association for Cancer Research.

In February, the U. S. Food and Drug Administration approved Kadcyla for monotherapy in patients with HER2-positive, metastatic breast cancer.  The full story:




Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Enter your email address to follow this blog and receive notifications of new posts by email.

%d bloggers like this: